T.M. Antalis
Queensland Cancer Fund Experimental Oncology Unit
The Queensland Institute of Medical Research
Brisbane 4029
Australia
Name/email consistency: low
- The serine proteinase inhibitor (serpin) plasminogen activation inhibitor type 2 protects against viral cytopathic effects by constitutive interferon alpha/beta priming. Antalis, T.M., La Linn, M., Donnan, K., Mateo, L., Gardner, J., Dickinson, J.L., Buttigieg, K., Suhrbier, A. J. Exp. Med. (1998)